Sign Up
Stories
Advancements in Huntington's Disease Treatment
Share
ALS Treatment Withdrawal: FDA Concerns
Alzheimer's Innovations: A Clinical Adva...
AMX0035 for PSP: Phase 3 Trial Commences
ANJESO Drug Insight and Market Forecast
Advancements in Cancer Treatment and Mar...
Overview
API
Neurocrine Biosciences reports positive Phase III data for Ingrezza, its drug for Huntington's disease, showcasing its ability to improve chorea in patients. Sage Therapeutics receives FDA Orphan Drug Designation for SAGE-718, a potential oral therapy for cognitive disorders in Huntington's disease. Roche partners with Ionis Pharmaceuticals to develop RNA-targeting programs for Alzheimer's and Huntington's diseases, leveraging Roche's strengths in nervous system disorders. FDA approves Neurocrine Biosciences' Ingrezza for chorea in Huntington's disease, potentially competing with Teva Pharmaceutical's Austedo.
Ask a question
How might the FDA's approval of Ingrezza for chorea in Huntington's disease influence the competitive landscape in the treatment of neurodegenerative disorders?
How might the advancements in treating Huntington's disease impact the quality of life for patients and their families?
What are the potential implications of the partnership between Roche and Ionis Pharmaceuticals for the development of RNA-targeting programs for Alzheimer's and Huntington's diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
May 2023
Jul 2023
Sep 2023
Coverage